Citigroup’s Ocular Therapeutix OCUL Stock Holding History

Citigroup’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,700	Closed	-$20K	–	7761
2019 Q3	$20K	Buy	+6,700	New	+$29.9K	﹤0.01%	6738
2019 Q2	–	Sell	-7,700	Closed	-$31K	–	7822
2019 Q1	$31K	Sell	7,700 -6,500	-46%	-$26.1K	﹤0.01%	6717
2018 Q4	$57K	Buy	14,200 +13,500	+1,929%	+$74.4K	﹤0.01%	6126
2018 Q3	$5K	Sell	700 -2,100	-75%	-$13.2K	﹤0.01%	7496
2018 Q2	$19K	Sell	2,800 -4,400	-61%	-$30.2K	﹤0.01%	6945
2018 Q1	$47K	Hold	7,200	–	–	﹤0.01%	6213
2017 Q4	$32K	Buy	7,200 +5,800	+414%	+$29.6K	﹤0.01%	6471
2017 Q3	$9K	Sell	1,400 -5,600	-80%	-$36.1K	﹤0.01%	6724
2017 Q2	$65K	Buy	7,000 +1,200	+21%	+$11.6K	﹤0.01%	5617
2017 Q1	$54K	Buy	+5,800	New	+$48.3K	﹤0.01%	5641

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citigroup's OCUL Position: Q1 2026 in Review

Citigroup reduced its Ocular Therapeutix (OCUL) stake by 91% in Q1 2026, selling an estimated $5.21M and leaving 55,777 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #3583.

Citigroup first reported a position in OCUL in Q3 2014 and has held it in 45 quarters since. The position peaked at $7.87M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Citigroup held 55,777 shares of Ocular Therapeutix worth $472K as of Q1 2026.
Citigroup sold 546,140 Ocular Therapeutix shares in Q1 2026, an estimated $5.21M.
Ocular Therapeutix made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3583 holding.
Citigroup first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 45 quarters since.
Citigroup's Ocular Therapeutix position peaked at $7.87M in Q3 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.